Unlocking Early-Stage Biotech: Dr Amir Zalcenstein on Transformative Science and Venture Capital

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. SYNthesis BioVentures is a registered early-stage venture Capital Limited partnerships fund, focused on early-stage therapeutics investing in projects from discovery through preclinical proof of concept and IND enabling studies. 

Amir and the team are investing in small molecule therapeutics, biologics and cell and gene therapies for conditions with significant unmet need. Their aim, to accelerate the development of cutting-edge therapies and technologies, ultimately improving patient outcomes and delivering value to their investors. 

Along with a PhD in molecular biology and an MBA, Amir has an extensive background in healthcare and international operations experience, having previously been head of business development for BiondVax, CEO of Amorphical and SoluBest, and a healthcare investment manager at OneVentures. 

In this episode you will hear about:

• How SYNthesis BioVentures is supporting early-stage research, 
• Opportunities to partner with overseas biotech firms and license underutilised, innovative therapies for western markets
• The challenges of financing biotech innovations, and the role of crossover funds in bridging early-stage investments with public markets 
• The importance of smart collaboration, and the need for startups to assemble a varied and knowledgeable team.

 Learn more about SYNthesis BioVentures

Updated version 05/08/22